334 related articles for article (PubMed ID: 21417961)
1. Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia.
Prescott H; Kantarjian H; Cortes J; Ravandi F
Expert Opin Emerg Drugs; 2011 Sep; 16(3):407-23. PubMed ID: 21417961
[TBL] [Abstract][Full Text] [Related]
2. FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.
Larrosa-Garcia M; Baer MR
Mol Cancer Ther; 2017 Jun; 16(6):991-1001. PubMed ID: 28576946
[TBL] [Abstract][Full Text] [Related]
3. FLT3 Inhibition in Acute Myeloid Leukemia.
Smith CC
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S5-S6. PubMed ID: 32862867
[TBL] [Abstract][Full Text] [Related]
4. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
Roskoski R
Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580
[TBL] [Abstract][Full Text] [Related]
5. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
[TBL] [Abstract][Full Text] [Related]
6. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
7. Targeting FLT3 to treat leukemia.
Konig H; Levis M
Expert Opin Ther Targets; 2015 Jan; 19(1):37-54. PubMed ID: 25231999
[TBL] [Abstract][Full Text] [Related]
8. Targeting FLT3 for the treatment of leukemia.
Small D
Semin Hematol; 2008 Jul; 45(3 Suppl 2):S17-21. PubMed ID: 18760705
[TBL] [Abstract][Full Text] [Related]
9. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Pemmaraju N; Kantarjian H; Andreeff M; Cortes J; Ravandi F
Expert Opin Investig Drugs; 2014 Jul; 23(7):943-54. PubMed ID: 24749672
[TBL] [Abstract][Full Text] [Related]
10. Emerging Flt3 kinase inhibitors in the treatment of leukaemia.
Tickenbrock L; Müller-Tidow C; Berdel WE; Serve H
Expert Opin Emerg Drugs; 2006 Mar; 11(1):153-65. PubMed ID: 16503833
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors.
Marensi V; Keeshan KR; MacEwan DJ
Biochem Pharmacol; 2021 Jan; 183():114348. PubMed ID: 33242449
[TBL] [Abstract][Full Text] [Related]
12. FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?
Pemmaraju N; Kantarjian H; Ravandi F; Cortes J
Cancer; 2011 Aug; 117(15):3293-304. PubMed ID: 21319142
[TBL] [Abstract][Full Text] [Related]
13. Will newer tyrosine kinase inhibitors have an impact in AML?
Levis MJ
Best Pract Res Clin Haematol; 2010 Dec; 23(4):489-94. PubMed ID: 21130412
[TBL] [Abstract][Full Text] [Related]
14. FLT3 inhibitors in AML: are we there yet?
Sudhindra A; Smith CC
Curr Hematol Malig Rep; 2014 Jun; 9(2):174-85. PubMed ID: 24682858
[TBL] [Abstract][Full Text] [Related]
15. Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.
Wang ES
Best Pract Res Clin Haematol; 2019 Jun; 32(2):154-162. PubMed ID: 31203997
[TBL] [Abstract][Full Text] [Related]
16. FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.
Langdon WY
Crit Rev Oncog; 2012; 17(2):199-209. PubMed ID: 22471708
[TBL] [Abstract][Full Text] [Related]
17. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
Kiyoi H; Kawashima N; Ishikawa Y
Cancer Sci; 2020 Feb; 111(2):312-322. PubMed ID: 31821677
[TBL] [Abstract][Full Text] [Related]
18. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
Stansfield LC; Pollyea DA
Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
[TBL] [Abstract][Full Text] [Related]
19. FLT3 inhibitors in acute myeloid leukemia.
el-Shami K; Stone RM; Smith BD
Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
[TBL] [Abstract][Full Text] [Related]
20. FLT3 inhibitors in acute myeloid leukemia: Current and future.
Thomas CM; Campbell P
J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
